The control of prostate-specific antigen expression and gene regulation by pharmacological agents - PubMed (original) (raw)
Affiliations
- PMID: 11171939
Review
The control of prostate-specific antigen expression and gene regulation by pharmacological agents
S C Dixon et al. Pharmacol Rev. 2001 Mar.
Abstract
Prostate-specific antigen is a serine protease that is a member of the kallikrein family. It is widely used as an indicator of tumor burden and as a surrogate marker for disease progression in men with androgen-independent prostate cancer. It has been shown that the expression and/or secretion of this glycoprotein can be regulated by pharmacological agents. The effects of these agents on PSA may be independent of their effects on cell growth. For example, a pharmacological agent may down-regulate PSA expression/secretion but have no effect on tumor cell growth. In this case, a patient receiving this therapeutic agent might be falsely considered as having a clinical response. Alternatively, an agent might up-regulate PSA expression/secretion and have an inhibitory effect on cell growth. A patient receiving this therapeutic agent might be diagnosed with progressive disease unless an alternative method for assessing tumor burden is used. Thus, when an agent is to be evaluated in a clinical trial utilizing PSA as a marker for disease progression, it is important to prospectively test whether the agent has an effect on PSA expression and/or secretion. In addition, it is equally important to understand how these regulatory effects relate to cell growth. The purpose of this review is to describe several agents that have been tested for their regulatory effects on PSA and to discuss potential mechanisms of by which this regulation may occur. The implications of these findings in the evaluation of new agents in androgen-independent prostate cancer will be considered.
Similar articles
- Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K. Fujii Y, et al. Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E927-31. doi: 10.1152/ajpendo.00443.2003. Epub 2004 Feb 3. Am J Physiol Endocrinol Metab. 2004. PMID: 14761877 - p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. Debes JD, et al. Cancer Res. 2005 Jul 1;65(13):5965-73. doi: 10.1158/0008-5472.CAN-04-2837. Cancer Res. 2005. PMID: 15994976 - Prostate specific antigen gene regulation by androgen receptor.
Kim J, Coetzee GA. Kim J, et al. J Cell Biochem. 2004 Oct 1;93(2):233-41. doi: 10.1002/jcb.20228. J Cell Biochem. 2004. PMID: 15368351 Review. - Expression and androgenic regulation of human prostate-specific kallikreins.
Young CY, Andrews PE, Tindall DJ. Young CY, et al. J Androl. 1995 Mar-Apr;16(2):97-9. J Androl. 1995. PMID: 7559150 Review.
Cited by
- White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft.
Wang X, Ha D, Mori H, Chen S. Wang X, et al. J Nutr Biochem. 2021 Mar;89:108580. doi: 10.1016/j.jnutbio.2020.108580. Epub 2020 Dec 31. J Nutr Biochem. 2021. PMID: 33388344 Free PMC article. - Recent development of highly sensitive protease assay methods: Signal amplification through enzyme cascades.
Yoon HK, Jung ST, Kim JH, Yoo TH. Yoon HK, et al. Biotechnol Bioprocess Eng. 2012;17(6):1113-1119. doi: 10.1007/s12257-012-0545-9. Epub 2013 Jan 4. Biotechnol Bioprocess Eng. 2012. PMID: 32218678 Free PMC article. Review. - Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.
Poniah P, Mohamed Z, Apalasamy YD, Mohd Zain S, Kuppusamy S, Razack AH. Poniah P, et al. Int J Clin Exp Med. 2015 Oct 15;8(10):19232-40. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26770559 Free PMC article. - Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over.
Mejak SL, Bayliss J, Hanks SD. Mejak SL, et al. PLoS One. 2013;8(2):e56030. doi: 10.1371/journal.pone.0056030. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418500 Free PMC article. - Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
Huang X, Chau CH, Figg WD. Huang X, et al. J Hematol Oncol. 2012 Jul 2;5:35. doi: 10.1186/1756-8722-5-35. J Hematol Oncol. 2012. PMID: 22747660 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous